Financials
| Interim results for the six months ended 30 Jun 25 | Sep. 03, 2025 |
| Interim results for the six months ended 30 Jun 25 | Aug. 21, 2025 |
| Audited results for the year ended 31 Dec 2024 | Apr. 24, 2025 |
| Q1 2025 Trading Update | Apr. 17, 2025 |
| Unaudited full year trading update | Feb. 05, 2025 |
| Q3 Trading Update | Oct. 29, 2024 |
| Interim results | Sep. 04, 2024 |
Proxies
| Result of AGM | May. 22, 2025 |
| Results of 2024 Annual General Meeting | Jun. 20, 2024 |
| Results of 2023 Annual General Meeting | Jun. 28, 2023 |
| Results of 2022 Annual General Meeting | Jul. 27, 2022 |
| AGM resolutions | Jul. 27, 2022 |
| Results of 2021 Annual General Meeting | Jun. 17, 2021 |
| Results of 2020 Annual General Meeting | Jun. 18, 2020 |
Ownership Update
| Grant of Share Options to Chief Executive Officer | Oct. 14, 2025 |
| Grant of Share Options | Feb. 13, 2025 |
| PDMR Transaction Notification | Nov. 27, 2023 |
| Holding(s) in Company | Jul. 24, 2023 |
| Grant of share options to the CEO | Jun. 06, 2023 |
| Holding(s) in Company | Jun. 01, 2023 |
| Holding(s) in Company | Jun. 01, 2023 |
Announcements
| Total Voting Rights | Oct. 01, 2025 |
| Positive efficacy and tolerance in pediatric trial | Oct. 01, 2025 |
| £1.5 million placing supporting growth of ACCRUFeR | Sep. 15, 2025 |
| Licence Agreement in Japan for ACCRUFeR® | Apr. 22, 2025 |
| ACCRUFeR® launched in Canada | Mar. 11, 2025 |
| Anders Lundstrom appointed CEO | Jan. 27, 2025 |
| Result of General Meeting & Total Voting Rights | Dec. 24, 2024 |